Item 5.02 Departure of Directors or Certain Officers; Election of Directors;
Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On July 24, 2020, Michael A. Kelly was appointed to serve on the Board of
Directors (the "Board") of DMC Global Inc. (the "Company").
Mr. Kelly has more than two decades of executive experience in senior leadership
roles in the life sciences industry. He founded and has served as President of
Sentry Hill Partners, LLC, a global life sciences transformation and management
consulting business, since January 2018. Mr. Kelly worked in various capacities
at Amgen, Inc. from 2003 to 2017, most recently as Senior Vice President, Global
Business Services from July 2014 to July 2017, and as acting Chief Financial
Officer from January to July 2014. Prior to his service at Amgen, he served as
Chief Financial Officer of Tanox, Inc. (2000 to 2003), Vice President, Finance
and Corporate Controller of Biogen, Inc. (1998 to 2000) and Vice President,
Finance and Chief Financial Officer of Nutrasweet Kelco Company (1996 to 1998).
He currently serves on the board of directors of HOOKIPA Pharma, Inc., a public
biopharmaceutical company, where he serves as an independent director and audit
committee chair. Mr. Kelly holds a bachelor's degree in Business Administration
from Florida A&M University.
The Board did not appoint Mr. Kelly to serve on any committees at this time.
There are no family relationships between Mr. Kelly and any officer or other
director of the Company or any related party transactions involving Mr. Kelly
and the Company. There is no arrangement or understanding between Mr. Kelly and
any other person pursuant to which he was selected as a director.
On July 24, 2020, Mr. Kelly received a grant of restricted stock awards with an
aggregate grant date fair value of $60,000, computed in accordance with FASB ASC
Topic 718. Mr. Kelly will be compensated for his service as a director in
accordance with the Company's standard director compensation program.
A copy of the press release announcing Mr. Kelly's appointment is included as
Exhibit 99.1 hereto.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits.
Exhibit Number Description
99.1 Press Release, dated July 2 7 , 2020.
Cover Page Interactive Data File (embedded within the Inline XBRL
104 document).
--------------------------------------------------------------------------------
© Edgar Online, source Glimpses